Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial.
Radhika NairNishita SinghMahesh Pundlik KateNegar AsdaghiRobert SarmientoFouzi BalaShelagh B CouttsMacKenzie HornAlexandre Y PoppeHeather WilliamsAyoola AdemolaIbrahim AlhabliFaysal BenaliHouman KhosravaniGary HunterAleksander TkachHerbert Alejandro Manosalva AlzateAleksandra PikulaThalia Shoshana FieldAnurag TrivediDariush DowlatshahiLuciana CataneseAshfaq ShuaibAndrew DemchukTolulope SajobiMohammed A AlmekhlafiRichard H SwartzBijoy MenonBrian H BuckPublished in: Stroke and vascular neurology (2024)
In this post-hoc analysis of patients with minor stroke enrolled in the AcT trial, safety and efficacy outcomes with tenecteplase 0.25 mg/kg were not different from alteplase 0.9 mg/kg.